IKIn-San Kim

In-San Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


In-San Kim has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Byungheon Lee

    Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

    2 shared publications
  • Chanju Lee

    Immuno-oncology Branch, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Republic of Korea

    2 shared publications
  • Eun Jung Park

    Department of Cancer Biomedical Science

    2 shared publications
  • Hee Jung Yoon

    Immuno-oncology Branch, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Republic of Korea

    2 shared publications
  • Ick Chan Kwon

    Medicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea

    2 shared publications
  • Minah Lee

    Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3

    by Seok-Min Lee, Minseong Kim, Chanju Lee, Minah Lee, Hee Jung Yoon, Byungheon Lee, Eun Jung Park, Soyoun Kim

    The therapeutic efficacy of blocking programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) can be augmented through combination with additional immune checkpoint inhibitors. Lymphocyte-activation gene 3 (Lag3) is an inhibitory checkpoint receptor that contributes to T-cell exhaustion and tumor immune evasion. We hypothesized that cotargeting PD-L1 and Lag3 using a human ferritin nanocage platform could provide an alternative therapeutic strategy to monoclonal antibodies (mAbs) against PD-L1 or Lag3 in modulating antitumor immune responses. Here, we describe a PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage (P1L2) displaying 24 PD-L1 binding peptides and 24 Lag3 binding peptides on its surface. P1L2 demonstrated simultaneous binding to both PD-L1 and Lag3 and exhibited stronger immune-stimulatory activity than either parent nanocage or mAbs against PD-L1 or Lag3. In a syngeneic mouse colon cancer model, P1L2 specifically targeted tumors and substantially suppressed tumor growth compared with each parent nanocage alone or in combination. Moreover, P1L2 showed more potent antitumor activity than a mAb against PD-L1 or Lag3 alone or in combination. These findings demonstrate that the PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage is a promising nanomedicine for cancer immunotherapy and has potential applications against various solid tumors.


  • Open Access

    Immune Checkpoint-Blocking Nanocages Cross the Blood–Brain Barrier and Impede Brain Tumor Growth

    by Minseong Kim, Hee Jung Yoon, Chanju Lee, Minah Lee, Rang-Woon Park, Byungheon Lee, Eun Jung Park, Soyoun Kim

    Glioblastoma (GBM) is the deadliest tumor of the central nervous system, with a median survival of less than 15 months. Despite many trials, immune checkpoint-blocking (ICB) therapies using monoclonal antibodies against the PD-1/PD-L1 axis have demonstrated only limited benefits for GBM patients. Currently, the main hurdles in brain tumor therapy include limited drug delivery across the blood-brain barrier (BBB) and the profoundly immune-suppressive microenvironment of GBM. Thus, there is an urgent need for new therapeutics that can cross the BBB and target brain tumors to modulate the immune microenvironment. To this end, we developed an ICB strategy based on the BBB-permeable, 24-subunit human ferritin heavy chain, modifying the ferritin surface with 24 copies of PD-L1-blocking peptides to create ferritin-based ICB nanocages. The PD-L1pep ferritin nanocages first demonstrated their tumor-targeting and antitumor activities in an allograft colon cancer model. Next, we found that these PD-L1pep ferritin nanocages efficiently penetrated the BBB and targeted brain tumors through specific interactions with PD-L1, significantly inhibiting tumor growth in an orthotopic intracranial tumor model. The addition of PD-L1pep ferritin nanocages to triple in vitro cocultures of T cells, GBM cells, and glial cells significantly inhibited PD-1/PD-L1 interactions and restored T-cell activity. Collectively, these findings indicate that ferritin nanocages displaying PD-L1-blocking peptides can overcome the primary hurdle of brain tumor therapy and are, therefore, promising candidates for treating GBM.


  • Hybrid Nanoparticle System Integrating Tumor-Derived Exosomes and Poly(amidoamine) Dendrimers: Implications for an Effective Gene Delivery Platform

    by Ashita Nair, Kaila Javius-Jones, Jason Bugno, Michael J. Poellmann, Narsimha Mamidi, In-San Kim, Ick Chan Kwon, Heejoo Hong, Seungpyo Hong


  • In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo

    by Sukyung Song, Man Kyu Shim, Seungho Lim, Yujeong Moon, Suah Yang, Jinseong Kim, Yeonsun Hong, Hong Yeol Yoon, In-San Kim, Kwang Yeon Hwang, et al.

    Exosomes are cellular components with promising uses in cancer diagnostics and therapeutics, and their imaging and tracking are essential to study their biological properties. Herein, we report on an in situ one-step fluorescence labeling strategy for exosomes via bioorthogonal click chemistry. First, exosome donor cancer cells were treated with tetraacetylated N-azidoacetyl-D-mannosamine (Ac4ManNAz) to generate unnatural azide groups (-N3) on their surface via metabolic glycoengineering. Then, the azide groups were labeled with near-infrared fluorescent dye-conjugated dibenzylcyclooctyne (DBCO-Cy5) via bioorthogonal click chemistry. After 2 days of incubation, the DBCO-Cy5-labeled exosomes (Cy5-Exo) were successfully secreted from the donor cancer cells and were isolated via classical ultracentrifugation, providing a high-yield of fluorescent dye-labeled exosomes. This in situ one-step bioorthogonal click chemistry offers improved labeling efficiency, biocompatibility and imaging sensitivy compared to standard exosomes (ST-Exo), purified with classical ultracentrifugation or carbocyanine lipophilic dye (DiD)-labeled exosomes (DiD-Exo) in vitro. In particular, the Cy5-Exo were successfully taken up by A549 cells in a time-dependent manner, and they could escape from lysosome confinement, showing their possible use as a delivery carrier of therapeutic drugs or imaging agents. Finally, intraveneously injected Cy5-Exo were non-invasively tracked and imaged via near-infrared fluorescence (NIRF) imaging in tumor-bearing mice. This new fluorescence labeling strategy for natural exosomes may be useful to provide better understanding of their theranostic effects in many biomedical applications.


  • Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine–Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth

    by Gijung Kwak, Dongkyu Kim, Gi-Hoon Nam, Sun Young Wang, In-San Kim, Sun Hwa Kim, Ick-Chan Kwon, Yoon Yeo

    Programmed cell death protein-1 (PD-1) is a prominent immune checkpoint receptor interacting with its ligand, programmed cell death protein ligand-1 (PD-L1, B7-H1). The PD-1/PD-L1 interaction induces functional exhaustion of tumor-reactive cytotoxic T cells and, thus, interferes with antitumor T-cell immunity. In addition, PD-1/PD-L1 interaction promotes tumorigenesis via the mTOR signaling pathway in a group of cancers including melanoma. Based on the dual functions of PD-1/PD-L1 interactions in tumor progression, we hypothesize that siRNA targeting PD-L1 (siPD-L1) will suppress melanoma growth, acting on both immune checkpoint and intrinsic tumorigenesis pathways. We tested this hypothesis by delivering siPD-L1 with a polymeric carrier (“pd”) consisting of disulfide-cross-linked polyethylenimine (CLPEI) and dermatan sulfate (DS), which we previously found to have a specific interaction with CD146-positive B16F10 melanoma cells. The siPD-L1/pd suppressed the expression of PD-L1 in the interferon-γ (IFN-γ)-challenged B16F10 melanoma cells in a cell-type dependent manner and attenuated the expression of tumor-specific genes in B16F10 cells. siPD-L1/pd suppressed the B16F10 melanoma growth in C57BL/6 immune-competent mice with increased tumor-specific immunity. siPD-L1/pd also suppressed melanoma growth in immune-compromised nude mice. Both animals showed a positive correlation between PD-L1 and p-S6k (a marker of mTOR pathway activation) expression in tumors. These results indicate that the siPD-L1/pd complex attenuates melanoma growth in both T-cell-dependent and independent mechanisms.